West Pharmaceutical Services Inc

WST retains its long-term uptrend, but near-term momentum has softened after price failed to sustain above the short-term EMAs. The Extreme OS context grants medium-term mean-reversion permission, enforcing a bullish medium-term bias, but current timing is unfavorable for immediate entry. Execution should be deferred—stalking for pullback acceptance into the EMA zone or the low-340 support area before engaging.

• ↑Q2 2026 revenue of $872M (+13% YoY); raised full-year organic growth to 10–11%.
• ↑Adjusted EPS rose 29% YoY to $2.37; gross margin up 200 bps to 37.7%.
• ↓Management warns demand still outpaces supply, risking capacity bottlenecks.